ProKidney Q1 net loss $36.9M, cash $463.7M; Phase 2 REACT enrollment complete

PROKIDNEY CORP.

Net loss before noncontrolling interest $36.9M vs $67.5M in Q1 2022; R&D spend $25.6M.
Cash, cash equivalents and marketable securities $463.7M as of March 31, 2023.
Completed enrollment in REGEN-007 Phase 2 study (53 subjects); initial data expected late 2023.
Phase 3 proact 1 enrollment ongoing; interim data targeted by end of 2024.
Preparing to initiate proact 2 Phase 3 study in EU, Latin America, Asia Pacific in H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PROKIDNEY CORP. reported the first quarter ended March 31, 2023 results: net income $36.9 million.

Period: the first quarter ended March 31, 2023
Net income: $36.9 million
Result: reported results

Exact text from the filing

On May 11, 2023, ProKidney Corp. issued a press release to announce its financial results for the quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

PROKIDNEY CORP. filing history →

Source: SEC EDGAR

accession 0000950170-23-021256

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.